Original Article

Assessing the Availability of Pharmacotherapy Options for Tobacco Cessation in Tennessee’s Substance Use Facilities

Authors: John Boatner, DSW, David Patterson, PhD, Freida Herron, DSW, William Nugent, PhD, Timothy Rice, MD

Abstract

Objectives: Smoking is deadly and exacerbates comorbid health conditions, especially among those with co-occurring substance use disorders. Tennessee does not require substance abuse treatment facilities to concurrently provide tobacco-cessation treatment options or limit smoking on facility property as a standard for licensure. This study examines the relation between Tennessee facility region and availability of pharmacotherapeutic options for tobacco cessation, and the relation between the facilities’ region and facility smoking policy.

Methods: This study is descriptive, cross-sectional, and exploratory in its design. Study findings are from a secondary analysis of data acquired from the 2016 edition of the National Directory of Drug and Alcohol Abuse Treatment Facilities published by the Substance Abuse and Mental Health Services Administration.

Results: The number of substance abuse treatment facilities providing pharmacotherapy options in west Tennessee (7.8%) are statistically significantly lower as compared with substance abuse treatment facilities in both middle (24.6%) and east (39.2%) Tennessee. A statistically significantly higher percentage of facilities in west Tennessee (23.5%) with policies that permit smoking without restriction as compared with the number of facilities in east Tennessee (6.8%) also was found, whereas the facilities in west Tennessee (60.8%) have a policy that permits smoking in designated areas that is significantly lower than the number of facilities in east Tennessee (81.1%).

Conclusions: Tobacco-cessation options are a preventive intervention that can be easily incorporated into a treatment facility’s standard of practice and should be made available within the context of all substance abuse treatment facilities. Failure to provide concurrent tobacco-cessation options during substance abuse treatment contradicts the purpose of medical treatment. Medically oriented substance abuse facilities are exemplary settings for offering pharmacotherapeutic options to concurrently treat tobacco use. It is suggested that interdisciplinary clinicians in the field of substance abuse advocate for the implementation of concurrent tobacco cessation treatment in their organization.

 

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Prochaska JJ. Failure to treat tobacco use in mental health and addiction treatment settings: a form of harm reduction? Drug Alcohol Depend 2010;110:177-182.
2. US Department of Health and Human Services. The health consequences of smoking-50 years of progress: a report of the Surgeon General. https://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html. Published 2014. Accessed April 23, 2019.
3. Xu X, Bishop EE, Kennedy SM, et al. Annual healthcare spending attributable to cigarette smoking: an update. Am J Prev Med 2015;48:326-333.
4. Baca CT, Yahne CE. Smoking cessation during substance abuse treatment: what you need to know. J Subst Abuse Treat 2009;36:205-219.
5. Gifford EV, Tavakoli S, Wang R, et al. Tobacco dependence diagnosis and treatment in Veterans Health Administration residential substance use disorder treatment programs. Addiction 2013;108:1127-1135.
6. Richman I, Krumholz HM. Lessons from the opioid epidemic to reinvigorate tobacco control initiatives. JAMA 2018;319:339-340.
7. Centers for Disease Control and Prevention. Smoking & tobacco use: fast facts. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm. Reviewed February 6, 2019. Accessed April 23, 2019.
8. Fagerström K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 2002;62(suppl 2):1-9.
9. Ziedonis DM, Guydish J, Williams J, et al. Barriers and solutions to addressing tobacco dependence in addiction treatment programs. Alcohol Res Health 2006;29:228-235.
10. Guydish J, Yu J, Le T, et al. Predictors of tobacco use among New York State addiction treatment patients. Am J Public Health 2015;105:e57-e64.
11. Prochaska JJ, Hall SE, Delucchi K, et al. Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial. Am J Public Health 2014;104:1557-1565.
12. Kalman D, Kim S, DiGirolamo G, et al. Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs. Clin Psychol Rev 2010;30:12-24.
13. Substance Abuse and Mental Health Services Administration. Tobacco use cessation during substance abuse treatment counseling. https://store.samhsa.gov/system/files/sma11-4636clin.pdf. Published 2011. Accessed April 23, 2019.
14. Simpkins CA, Simpkins AM. Neuroscience for Clinicians: Evidence, Models, and Practice. New York:Springer;2013.
15. Rogers E, Sherman S. Tobacco use screening and treatment by outpatient psychiatrists before and after release of the American Psychiatric Association treatment guidelines for nicotine dependence. Am J Public Health 2014;104:90-95.
16. Laschober TC, Eby LT. Counselor and clinical supervisor perceptions of OASAS tobacco-free regulation implementation extensiveness, perceived accountability, and use of resources. J Psychoactive Drugs 2013;45:416-424.
17. Gulliver SB, Kamholz BW, Helstrom AW. Smoking cessation and alcohol abstinence: what do the data tell us? Alcohol Res Health 2006;29:208-212.
18. Thurgood SL, McNeill A, Clark-Carter D, et al. A systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery. Nicotine Tob Res 2016;18:993-1001.
19. Schroeder SA, Morris CD. Confronting a neglected epidemic: tobacco cessation for persons with mental illnesses and substance abuse problems. Annu Rev Public Health 2010;31:297-314. 1p following 314.
20. Substance Abuse and Mental Health Services Administration. The N-SSATS report: tobacco cessation services. https://www.samhsa.gov/data/sites/default/files/N-SSATS%20Rprt%20Tobacco%20Cessation%20Services/The%20N-SSATS%20Report%20%20Tobacco%20Cessation%20Services/The%20N-SSATS%20Report%20%20Tobacco%20Cessation%20Services.htm. Published 2013. Accessed May 4, 2019.
21. Krauth D, Apollonio DE. Overview of state policies requiring smoking cessation therapy in psychiatric hospitals and drug abuse treatment centers. Tob Induc Dis 2015;13:33.
22. Substance Abuse and Mental Health Services Administration. National survey of substance abuse treatment services (N-SSATS): 2015. Data on substance abuse treatment facilities. https://www.samhsa.gov/data/sites/default/files/2015_National_Survey_of_Substance_Abuse_Treatment_Services.pdf. Accessed April 23, 2019.
23. Raymond M, Rousset F. An exact text for population differentiation. Evolution 1995;49:1280-1283.
24. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 2000;151:531-539.
25. Knudsen HK. Implementation of smoking cessation treatment in substance use disorder treatment settings: a review. Am J Drug Alcohol Abuse 2017;43:215-225.